E. Ferrer1, E. Valls-Pascual1, D. Ybáñez-García1, J. J. Alegre-Sancho1.

mainly involves the use of systemic therapies, which often have limited efficacy.

Background:

Conclusion:

edges due to the ointment preparation, which was resolved by protecting

adverse effect has been detected, except for slight maceration of the wound

improvement in pain, function, quality of life and satisfaction of the patients).

calcinosis foci and partial or complete healing of the ulcers together with an

improvement in the needed cures, healing time and pain).

moist healing environment shows some advantages over the dry cure (exudate

wounds and perilesional skin cleaning and disinfection is performed and, if

Disclosure of Interests:

Disclosure of Interests:

Conclusion:

In our experience, treatment with TST for calcinosis-associated

Results: Nine patients (7 women) with calcinosis-associated skin ulcers and SSc were included: 2 patients with diffuse SSc (DcSSc), 6 with limited SSc (LcSSc) and 1 with overlap syndrome. Median age was 60 years (IQR 20), 6 patients had localized wounds and 3 had extensive involvement and/or
tumoral calcinosis which had been refractory to systemic treatment with
diltiazem, colchicine, zoledronate, rituximab, and/or acenocoumarol and had suffered recurrent superinfections. Follow-up results of more than 3 months are available for 8 patients, who have been on TST a median time of 9 months (IQR 8.25). They have shown clinical improvement (disappearing of many calcinosis foci and partial or complete healing of the ulcers together with an improvement in pain, function, quality of life and satisfaction of the patients).

Radiological improvement was also observed in 1 case. No TST related adverse effect has been detected, except for slight maceration of the wound edges due to the ointment preparation, which was resolved by protecting these with zinc oxide cream

Conclusion: In our experience, treatment with TST for calcinosis-associated skin ulcers in patients with SSc is an effective, safe and easily implementable therapeutic alternative in clinical practice.

Disclosure of Interests: Inmaculada Torner Hernández: None declared, A Sendra-García: None declared, V Núñez-Monje: None declared, L Montolío-Chiva: None declared, Ana V Orenes Vera: None declared, I Vázquez-Gómez: None declared, Maribel Mora: None declared, Xavier González: None declared, Carla Marco: None declared, Á Martinez-Ferrer: None declared, Montserrat Romera: None declared, Joan Miguel Nolla: None declared

DOI: 10.1136/annrheumdis-2020-eular.4778

AB0595

EFFECTIVENESS OF TOPICAL SODIUM THIOSULFATE TREATMENT OF CALCINOSIS-ASSOCIATED CUTANEOUS ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS

I. Torner Hernández1, A. Sendra-García1, V. Núñez-Monje1, L. Montolío-Chiva1, A. V. Orenes Vera1, I. Vázquez-Gómez2, E. Flores Fernández2, Á. Martinez-Ferrer2, E. Valls-Pascual3, D. Ybáñez-García3, J. J. Alegre-Sancho3, 1Hospital Universitari Dr Peset, Rheumatology, Valencia, Spain

Background: Treatment of calcinosis associated with systemic sclerosis (SSc) mainly involves the use of systemic therapies, which often have limited efficacy. However, little attention has been paid to local treatment, which is especially useful when associated with skin ulcers.

Objectives: To show our experience with topical sodium thiosulfate (TST) for the treatment of calcinosis-associated cutaneous ulcers in patients with SSc.

Methods: Descriptive analysis of a case series of patients with SSc and calcinosis-associated skin ulcers treated with TST. Wound management procedure: wounds and perilesional skin cleaning and disinfection is performed and, if needed, additional debridement. TST is compounded at 25%, w/v emulsion, for extensive calcinosis, or as beeler-base or cold-cream ointment, for limited calcinosis. Wounds are then covered with a polymeric foam dressing. This cure in

Disclosure of Interests: None declared, Elia Valls-Pascual Grant/research support from: Roche, Novartis, and Abbvie, Speakers bureau: Abbvie, Lilly, Pfizer, MSD, Novartis, Janssen, Bristol Myers Squibb, UCB Pharma, D Ybáñez-García Speakers bureau: Lilly, Roche, Sanofi, Juanjo J Alegre-Sancho Consultant of: UCB, Roche, Sanofi, Boehringer, Celltrion, Paid instructor for: GSK, Sanofi, Abbvieve, Lilly, Roche, UCB, Actelion, Pfizer, Abbvie, Novartis

DOI: 10.1136/annrheumdis-2020-eular.2562

AB0596

PREDICTORS, LONG TERM CLINICAL AND TREATMENT OUTCOMES IN SOUTH ASIAN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS: A SINGLE CENTER STUDY

A. Nair1, R. Goel1, P. Chebbi1, A. Mathew2, A. Ganapati2, G. Rebek2, B. Yadav1, J. A. J. Prakash1, D. Danda1, J. Mathew1, 1Christian Medical College Hospital, 2Christian Medical College, Vellore, India, 3Christian Medical College, Vellore, Biostatistics, Vellore, India, 4Christian Medical College, Vellore, Microbiology, Vellore, India

Background: Idiopathic inflammatory myositis (IM) are a heterogeneous group of immune-mediated disorders with varied presentations and multiple organ involvement. Data on long term outcome among South Asian patients with IM is sparse.

Objectives: To study the long term clinical outcome, treatment responses and factors predicting outcome among adult patients with IM

Methods: Patients diagnosed as ‘Idiopathic Inflammatory Myositis’ under the department of Clinical Immunology and Rheumatology at CMC, Vellore, India were screened retrospectively. Patients aged 18 years and above, satisfying Bohan and Peter criteria, having follow up of one year or more with at least two outpatient or inpatient visits between January 2010 and April 2019 were included in this study. Those patients with connective tissue disease associated calcinosis were not included. Details on muscle weakness, extramuscular involvement, muscle enzymes and treatment administered were recorded at baseline, 3, 6, 12, 18, 24 months and yearly thereafter. After assessing their cumulative response, categorization of patients into complete and partial responders was done. Complete responders were defined as patients with persistent muscle power of more than 4/5 and/or MMT 8 more than 75/80, complete resolution of skin, articular and lung involvement (if any) as well as muscle enzymes less than twice the upper limit of normal without any documented flares during the entire follow up period. Patients not satisfying the said criteria were grouped as Partial responders. Disease free survival duration was also analyzed.

Results: Out of 310 patients of IM identified, 187 (60.3%) patients satisfied the inclusion criteria. Women were 2.2 times more than men and mean age at symptom onset was 35.7±12.6 years. Dermatomyositis was the predominant myositis subtype seen. All patients were put on steroids with the mean dose being 45.9 ± 18.6 mg/day. At baseline, the key immunosuppressants used were methotrexate in 44.9% and mycophenolate in 37.6% patients. The median follow up duration was 48 (25-80) months. An associated malignancy was diagnosed in 3.2% after a median duration of 24.5 months. Five patients expired after a median duration of 60 months from diagnosis. Normal muscle power was attained in 76.1% patients and 88.6% were vocational by the last follow up visit. Steroids were discontinued in 56.7% patients after a median duration of 24 months (p=0.0002). Discontinuation of the immunosuppressant was feasible in 10.2% patients after a median duration of 44 months. Assessment of...